Literature DB >> 28739722

GRP78 Participates in PCA3-regulated Prostate Cancer Progression.

Chunhua Lin1, Jiahui Wang2, Yanwei Wang2, Peng Zhu2, Xin Liu2, Ning Li2, Juan Liu2, Luxin Yu3, Wenting Wang4.   

Abstract

BACKGROUND/AIM: The human prostate cancer antigen 3 (PCA3) is a long non-coding RNA (lncRNA) commonly used as a diagnostic marker for prostate cancer (PCa). Herein we investigated the cellular function of PCA3 in PCa and its potential mechanism.
MATERIALS AND METHODS: PCA3 was overexpressed in a PC3 cell line (PC3PCA+) and cell proliferation, migration, invasion and apoptosis were compared to those of control cells (PC3NC). Differentially expressed proteins were identified by two-dimensional polyacrylamide gel electrophoresis (2D-PAGE) and mass spectrometry.
RESULTS: Overexpression of PCA3 significantly increased cell proliferation rate, migration and invasion, while inhibited apoptosis in PC3 cells. Three proteins were found down-regulated and 7 proteins up-regulated in PC3PCA+ cells compared to PC3NC cells, including GRP78. Higher GRP78 was also found in PCa clinical specimens.
CONCLUSION: This study confirmed that in PCa, PCA3 plays a pro-cancer role through promoting cell proliferation, migration and invasion while inhibiting cell apoptosis. This process might involve the up-regulation of GRP78. Copyright
© 2017, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  GRP78; PCA3; Prostate cancer; cancer-related genes; long non-coding RNA

Mesh:

Substances:

Year:  2017        PMID: 28739722     DOI: 10.21873/anticanres.11823

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  9 in total

1.  Cell division cycle associated 2 (CDCA2) upregulation promotes the progression of hepatocellular carcinoma in a p53-dependant manner.

Authors:  Jiahui Wang; Xin Liu; Hongjin Chu; Jian Chen
Journal:  PeerJ       Date:  2022-06-06       Impact factor: 3.061

2.  Liquid Biopsy Potential Biomarkers in Prostate Cancer.

Authors:  Jochen Neuhaus; Bo Yang
Journal:  Diagnostics (Basel)       Date:  2018-09-21

3.  miR‑15a‑3p affects the proliferation, migration and apoptosis of lens epithelial cells.

Authors:  Shu-Jun Liu; Wen-Ting Wang; Feng-Lan Zhang; Yong-Hong Yu; Hua-Jun Yu; Yan Liang; Ning Li; Yuan-Bin Li
Journal:  Mol Med Rep       Date:  2018-12-11       Impact factor: 2.952

4.  LncRNA LINC00665 Promotes Prostate Cancer Progression via miR-1224-5p/SND1 Axis.

Authors:  Wei Chen; Zhixian Yu; Weiping Huang; Yu Yang; Feng Wang; Hang Huang
Journal:  Onco Targets Ther       Date:  2020-03-26       Impact factor: 4.147

5.  Importance of PNO1 for growth and survival of urinary bladder carcinoma: Role in core-regulatory circuitry.

Authors:  Chunhua Lin; Hejia Yuan; Wenting Wang; Zhe Zhu; Youyi Lu; Jiahui Wang; Fan Feng; Jitao Wu
Journal:  J Cell Mol Med       Date:  2019-12-04       Impact factor: 5.310

6.  Effect of upregulation of DD3 on early detection and prognosis in prostate cancer.

Authors:  Ke Wang; Huishan Zhao; Wenting Wang; Yingqian Zhu; Xuebao Zhang; Jiajia Ma; Haotian Tan; Yulian Zhang; Chunhua Lin
Journal:  Transl Androl Urol       Date:  2020-08

7.  Centromere Protein I (CENP-I) Is Upregulated in Gastric Cancer, Predicts Poor Prognosis, and Promotes Tumor Cell Proliferation and Migration.

Authors:  Jiahui Wang; Xin Liu; Hong-Jin Chu; Ning Li; Liu-Ye Huang; Jian Chen
Journal:  Technol Cancer Res Treat       Date:  2021 Jan-Dec

8.  Retracted Article: Long noncoding RNA PCA3 regulates glycolysis, viability and apoptosis by mediating the miR-1/CDK4 axis in prostate cancer.

Authors:  Shuo Gu; Xiaobing Niu; Fei Mao; Zongyuan Xu
Journal:  RSC Adv       Date:  2018-11-08       Impact factor: 4.036

9.  PGK1 and GRP78 overexpression correlates with clinical significance and poor prognosis in Chinese endometrial cancer patients.

Authors:  Suiqun Guo; Yanyi Xiao; Danqing Li; Qingping Jiang; Litong Zhu; Dan Lin; Huiping Jiang; Wei Chen; Lijing Wang; Chunhua Liu; Weiyi Fang; Li Lin
Journal:  Oncotarget       Date:  2017-12-07
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.